Cybin has completed more than 20 pre-clinical studies in record time. Company is advancing two new therapeutic candidates with enhanced, improved properties. Drug candidates are designed to treat serious psychiatric conditions with high unmet medical…
Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, today announced its entry into a drug development agreement with Catalent (NYSE: CTLT), the leading global provider of advanced delivery technologies, development…
Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has announced completion of its 20th preclinical study and is progressing its CYB003 and CYB004 proprietary psychedelic molecules into Investigational New Drug…
Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has announced that its Chief Executive Officer, Doug Drysdale, will be presenting a business and pipeline update at the Oppenheimer 31st Annual…
Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has announced that its Chief Executive Officer, Doug Drysdale, will be presenting a business and pipeline update at the M Vest and…
Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, today announced that its Chief Executive Officer, Doug Drysdale, will be presenting a business and pipeline update at the Stifel GMP Health…
Cybin’s latest offering generated exceptional demand; announces upsize of “bought deal” offering Burgeoning psychedelic sector attracts investors’ attention as compound may prove effective in mental health treatments. Cybin appears set for rapid growth as research…
Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, today announced that its shares have commenced trading on the OTCQB(R) Venture Market under the symbol “CLXPF.” “With the commencement of trading…
Adelia Therapeutics has achieved earn-out milestones outlined in contribution agreement with Cybin Adelia ideal acquisition for Cybin, as it leads innovation in researching psychedelic treatment options in the mental health space Acquisition results in Cybin…
Cybin (NEO: CYBN) (OTC: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, today announced its successful uplisting from the OTC Pink Sheets to the OTCQB(R) Venture Market. Cybin will commence trading on the OTCQB…